Transactions on Materials, Biotechnology and Life Sciences
ISSN: 2960-1932, eISSN: 2960-2319 | Volume 8
MMTCS 2025

The Growing Threat of Antibiotic Resistance: A Public Health Crisis

Yuhan Liu*

UC Riverside, Riverside, USA

* Corresponding Author Email: nybigapplenl@gmail.com

Abstract. Antibiotic resistance is a mounting worldwide health crisis that undermines the very foundations of modern medicine. During these practices, prescription and overprescription of antibiotics in healthcare, noncompliance with the therapy by the patient, mass usage in agriculture, environmental pollution, and the contemporary increment of international travel contribute to the spread of antibiotic resistance. It explores how infectious diseases—particularly in the developing world—share the blame through mismanagement and ailing health systems. The misuse of antibiotics to treat viral infections, particularly during events such as the COVID-19 pandemic, has led to an increase in resistance. The paper emphasizes strategies to combat this increasingly urgent risk: implementing antimicrobial stewardship programs, reforming antibiotic use in agriculture, investing in establishing new drugs and vaccines, improving global surveillance, and educating the public. These comprehensive solutions—grounded in a One Health perspective—are critically and urgently needed to curb resistance, protect current treatments, and preserve global health security against newly emerging bacterial challenges.

Keywords: antibiotic resistance, hygiene, medication, environmental contamination, agriculture, indiscriminate use of antibiotics in food-producing animals.

1. Introduction

The threat of antibiotic resistance stands as one of the most critical public health dangers during the 21st century. The discovery of antibiotics in the early 1900s enabled the treatment of bacterial infections and made possible surgical procedures, chemotherapy, and organ transplant support. The misuse of antibiotics in humans, animals, and agriculture has resulted in bacteria developing drug resistance. The World Health Organization (WHO) reports (2020) that antibiotic resistance continues to increase worldwide, which creates severe risks for health systems, food security, and economic stability. The world could enter a "post-antibiotic era" if antibiotic resistance continues to grow because infections that were previously treatable will become fatal. This paper examines the origins of antibiotic resistance, together with disease involvement and resulting effects, and available remedies for this crisis, while emphasizing the necessity of unified action.

2. Key Drivers of Antibiotic Resistance

One of the main Antibiotic-resistant organisms arises as a result of interactions between behavioral, ecological, and systemic forces. The four main causes are overprescription and misuse in healthcare, patients not complying with medication, agricultural overuse, and environmental contamination.

First, antibiotics are frequently used when they are not needed. In the United States, 30% of antibiotic prescriptions in outpatients are unjustified (Centers for Disease Control and Prevention [CDC], 2019). Doctors may prescribe antibiotics for the common cold or the flu to alleviate patients' expectations or because they have doubts about the actual nature of the infection. This overuse exposes bacteria to antibiotics even as it kills them, and allows resistant strains to survive and multiply. Moreover, in many countries, counter antibiotics can be purchased without the need for a prescription, some with little regulations on antibiotic distribution. This unrestricted access magnifies the problem.

Second, even if doctors use antibiotics correctly to treat a specific infection, such as strep throat, a patient's noncompliance in following the recommended treatment can lead to the recurrence of the infection and increase the likelihood that others in the community will become infected with antibiotic-resistant bacteria. Additionally, people stop taking antibiotics too soon when they're feeling better, thinking that the infection is gone. Premature cessation of treatment, however, can permit surviving bacteria, especially the most resistant organisms, to proliferate and develop drug resistance (Ventola, 2015). A well-known example is inadequate therapy of infections with Streptococcus pneumoniae. If the antibiotic treatment is not continued to completion, the bacteria may not all be destroyed, and there is the potential for relapse with more resistant strains. That resistance makes subsequent infections harder to treat, sometimes with powerful or more toxic antibiotics. Moreover, leftovers of antibiotics are often kept for next time treatment, shared with others, or sold, or started without consulting the pharmacists, especially where the over-the-counter (OTC) use of the antibiotics is frequent. These practices not only jeopardize health in an individual but also make bacteria encounter subtherapeutic doses, which drives resistance (WHO, 2020).

Public health messages should not just concern rational use or prescription but also be geared towards educating patients on the value of adherence and the risks of sharing and hoarding antibiotics.

Third, an underestimated contributor to the global crisis is the overuse of antibiotics in agriculture, and particularly in animal farming. On industrialized farms, animals receive antibiotics whether they are sick or not, to treat disease or to grow faster and prevent illness in unsanitary, crowded conditions.

Nowadays, more than 70 percent of all medically important antibiotics sold in the United States are used across all food-producing animals, according to the U.S. Food and Drug Administration (FDA, 2021). This widespread use makes development of antibiotic-resistant bacteria in animals likely, and the bacteria can be spread to humans in several ways: when people eat undercooked food; when they consume water or produce that has been contaminated during cultivation; or when they have direct contact with the animals or their environments.

Resistant pathogens, like methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing E. coli, have been associated with farm sources and have been responsible for outbreaks in humans. The worry is not just direct transmission but horizontal gene transfer – resistance genes in animal bacteria can move to human pathogens. This gene transfer also confuses resistance dynamics, making it more difficult to follow and contain new threats. Measures adopted to address the issue, such as the prohibition of the use of antimicrobials for non-therapeutic reasons, guidelines on veterinary prescriptions, and the spreading of Antibiotic Stewardship in animal rearing, have now become imperative for the conservation of animal and human health.

Fourth, another rising issue is the contribution of the environment as a source of antibiotic resistance. Pharmaceutical factories, hospitals, and homes in many countries, particularly in some parts of Asia and Africa, discharge untreated or inadequately treated wastewater into rivers, lakes, and the environment around farms. Such effluents can harbor active antibiotics, antibiotic-resistant bacteria, and resistance genes, and can be released into the wild where they contaminate natural ecosystems and form “hotspots” for resistance evolution (Larsson et al., 2018). When such low-level antibiotics are washed into soil and water, bacteria there can also encounter and develop resistance to them, and then share that resistance with other bacteria through a kind of gene exchange called horizontal transfer. These resistant bacteria can spread into local food chains, irrigation systems, or even tap water, and into human populations with no direct exposure to health care or medicines.

Hospitals are also major contributors to environmental pollution. Waste water from hospitals not only contains antibiotics but also a high burden of resistant strains, especially from intensive care units or surgical departments. In the absence of waste management, such waste can also penetrate the surrounding environment and add to the exposure at the local level.

Preventing enhanced occupational and environmental exposure to antibiotics and resistance genes With Anglesey Communities 24-25-26th November 2009 (24th & 25th Science) Scottish Association for Marine Science, Research Park, Dunstaffnage, Oban, Scotland, UK Environmental contamination can induce adverse consequences that need to be considered and regulated by either limiting concentrations available, developing suitable waste treatment infrastructure, or through the adequacy of international practices to halt uncontrolled pollutant spread to the environment and food.

Fifth, nowadays, when the world is more connected than ever, globalization and international travel are the main causes of the quick dissemination of resistant bacteria. Foreign trips for tourists, businesspeople, or patients who have surgery or other treatments in other countries can lead to the spread of drug-resistant infections, even from unknown sources of exposure, like the organisms found in hotel plumbing or bacteria picked up at the bedside of someone else. This is especially worrisome if travelers are treated in countries of increased antibiotic resistance (i.e. if surgeries or dentistry are performed, Brockmann & Helbing, 2013). One of the most notorious examples of spread is NDM-1 (New Delhi metallo-beta-lactamase-1), an enzyme that gives bacteria immunity to a broad spectrum of antibiotics. Originally discovered from a patient repatriating to the UK from India, NDM-1 has now been reported from more than 70 countries, mostly as a consequence of international travel and lax infection control in some medical centers (Kumarasamy et al., 2010). International trade of food, animals, and pharmaceuticals also promotes the spread of resistant strains across borders. Resistant bacteria present in the imported meat or produce could avoid inspections and end up on retail shelves and, from there, into consumers' bodies, where they could sicken but not kill. This emphasizes the importance of international surveillance networks, common report formats, and coordinated public health strategies. In an era of globalization, combating resistance requires us to take a One Health approach — an approach that considers the health of humans, animals, and the environment as interconnected entities within the global context.

3. The Role of Infectious Diseases in Driving Resistance

Apart from the five main causes of the antibiotic resistance crisis, it is also important to explain the role of disease in this crisis. Diseases are both drivers and victims of antibiotic resistance. Infectious diseases, whether viral or bacterial, often serve as the starting point for antibiotic misuse and the evolution of resistance. In numerous low- and middle-income countries (LMICs), rates of bacterial infectious diseases, such as tuberculosis (TB), cholera, and typhoid fever, continue to be unacceptably high. These infections are curable with antibiotics; however, weak health services, low access to drugs, absence of diagnostic facilities, and fragile public health systems lead to misuse and irrational treatment. Patients may still not receive a complete course of the right drugs or may not finish their antibiotics based on cost, side effects, or denial of care (World Health Organization [WHO], 2020). All of these conditions provide fertile ground for the emergence of drug-resistant strains, as has happened worldwide in the case of MDR-TB and XDR-TB. For instance, MDR-TB could be born after patients are treated with the wrong drug combinations or when healthcare systems do not ensure patients stick to treatment throughout its protracted duration. XDR-TB resistant to both first and second-line drugs is now a major threat worldwide, particularly in parts of South Asia and sub-Saharan Africa (WHO, 2020). Cholera—a bacterial infection associated with contaminated water—also sparks rampant, largely unregulated use of antibiotics. In places with poor sanitation, where people lack access to clean water, the consumption of antibiotics in response to repeated cholera outbreaks at the community level has helped to create resistance that can then spread more widely among the population. Typhoid fever is also an example of how a high burden of disease has led to resistance to a life-saving drug. In many places, antibiotics such as ciprofloxacin are no longer effective after decades of overuse; instead, new, more expensive, toxic drugs must be deployed (Andrews et al., 2018). These are examples of how the burden of persistent infectious diseases with weak health systems directly drives the emergence and spread of antimicrobial resistance worldwide.

Apart from high disease burdens, one of the main, but usually ignored, causes of antibiotic resistance is the misuse of antibiotics to treat viral infections, for which they have no curative value. Common knowledge in medicine has failed to liberalize the prescribing of antibiotics to illnesses such as the common cold, influenza, or bronchitis, and now, more recently, COVID-19. This overprescription is a consequence of patient pressure, diagnostic doubt, and healthcare provider fear, especially in outpatient care. At the beginning of the COVID-19 pandemic, fear and uncertainty resulted in an unprecedented surge in the use of antibiotics. A study by Rawson et al. (2020) identified that over 70% of COVID-19 hospitalized patients were treated with antibiotics, although less than 10% had been diagnosed with bacterial co-infection. The overuse was likely due to anxiety about potential secondary bacterial infections, absence of rapid diagnostic tests, and strain on overwhelmed medical systems, they said. But the result was a rapid rise in hospital-acquired resistant infections, like carbapenem-resistant Enterobacteriaceae (CRE) and other multidrug-resistant organisms. Similar behavior has been seen during seasonal influenza — a doctor may 'cover themselves' and give out antibiotics 'just in case' if they suspect any secondary causes to the primary viral illness. Although well-intentioned, this defensive prescribing unnecessarily exposes patients to antibiotics and fuels an increase in resistance. To interrupt this cycle, healthcare practitioners need to be provided with rapid diagnostics, more prescriptive categories for diagnosis and patient education, to encourage people to be aware of and manage their conditions, and we must ensure that antibiotics are only used when there is a clear bacterial explanation. The role of disease affects the antibiotic resistance crisis from both external and internal factors.

Following viral infection, the immune response becomes weakened, and viral-infected patients become susceptible to secondary bacterial infections. For instance, the flu can cause bacterial pneumonia, which would need to be treated with antibiotics. If the bacteria causing pneumonia are resistant, treatment becomes harder. This convergence of viral with bacterial disease adds to the force to perform antibacterial treatment, thereby also promoting resistance. The distinction between primary viral and secondary bacterial infections further complicates clinical decision-making. Patients with chronic conditions like cancer, diabetes, or HIV/AIDS tend to have weakened immune systems, which puts them at increased risk of infections. These people are often in desperate need of antibiotics—either to treat existing diseases or to protect themselves from complications during hospital procedures. Hence, they are at increased risk for nosocomially acquired resistant bacteria and consequently, a growing demand on healthcare services. For instance, cancer patients who are receiving chemotherapy have a high likelihood of developing febrile neutropenia and are often given precautionary broad-spectrum antibiotics that lead to resistance over time.

4. Strategies to Combat Antibiotic Resistance

Although antibiotic resistance is a major threat, fortunately, its consequences can be greatly mitigated. First, antimicrobial stewardship programs have become increasingly mandatory elements of medical practice. Comprehensive antimicrobial stewardship programs (ASPs) are necessary for preventing antibiotic resistance. Such strategies are designed to reduce the consumption of antibiotics by only prescribing them when they are clinically indicated, and then choosing the appropriate drug, dose, and duration on the basis of both the patient's condition and the specific pathogen involved (CDC, 2019). Preventing the misuse of antibiotics in the treatment of viral infections, which provides no benefit but enhances resistance, is one of the primary objectives of ASPs. The development of rapid diagnostics is an important part of successful stewardship. These techniques, such as molecular tests and point-of-care instruments, can make the distinction between whether an infection is due to a bacterium or a virus in minutes. For example, tests currently available that ascertain C-reactive protein (CRP) and procalcitonin (PCT) levels aid in the decision for antibiotic therapy to minimize unnecessary prescription of antibiotics in primary care (Karanika et al., 2016). ASPs also focus on staff education of healthcare providers, continuous surveillance of their prescribing, and feedback mechanisms to detect excessive use. Hospitals that have implemented robust stewardship programs have seen reductions in antibiotic use, lower rates of infection with resistant bacteria, and better patient outcomes. National and worldwide health systems need to consider expanding and ensuring implementation of those programs in both inpatient and outpatient settings.

Second, policy reform in agriculture. Antimicrobial resistance and indiscriminate use of antibiotics in food-producing animals. Antimicrobial resistance is closely associated with the misuse and overuse of antibiotic drugs in food-producing animals. To counteract this, governments should establish strict legislation concerning the prescription of antibiotics in food animals and ban their use for growth promotion, and limit their use for therapy. The European Union has already established such regulations that prohibit the use of antibiotics for growth promotion in 2006 and for preventive purposes in 2022 (European Medicines Agency, 2022). Other countries, like the United States and Canada, are starting to do the same with voluntary guidelines and veterinary feed directives. But enforcement is uneven, and loopholes frequently allow abuse to persist. However, mandatory policy should be implemented with strong enforcement and punitive measures to ensure it is enforced and human health is protected.

Consumer behaviour is also a key factor. With public attention on the rise, many consumers are beginning to demand meat, eggs, and dairy products that are free of antibiotics. Programs such as USDA Organic and Certified Responsible Antibiotic Use (CRAU) give consumers labels to help them identify responsibly raised products. Industry practices can also be further impacted by public awareness of such information regarding food labeling and the impact of antibiotic resistance in the long term. By being well-informed, consumers can help create demand for sustainable farming and pressure food companies to demand better standards.

Third, research and innovation. It is a major part of the campaign against resistance because current antibiotics are decreasing in their effectiveness. But a promising stream of new antibiotics has become a trickle in recent decades, as few new classes of antibiotics have made their way to the market. That's because developing antibiotics is expensie, and brings in less profit than drugs for chronic conditions do. Consequently, many pharma companies had turned their backs on antibiotics. To break away from this cycle, governments and intergovernmental organizations should provide incentives to pharmaceutical companies in the form of grants, market entry rewards, extensions of patent protection, and partnerships between public and private enterprises. One such initiative is the Global Antibiotic Research and Development Partnership (GARDP) that is working on inexpensive novel antibiotics for resistant infections, especially of relevance to resource-poor populations. In addition to the conventional antibiotics, novel strategies, including bacteriophage therapy, antimicrobial peptides, and CRISPR-based genome editing techniques, are thought to be potential options for the elimination of resistant bacteria. Vaccines are also important to invest in, as they can prevent infection, reducing the need for antibiotics in the first place. An obvious illustration is with the introduction of pneumococcal vaccines, which have dramatically reduced the incidence of S. pneumoniae, one of the most common resistant organisms (O'Brien et al., 2009). Only global cooperation and ongoing financial investment can keep the pipeline of new treatments flowing to benefit everyone.

Fourth, using and creating systems for global surveillance and response. Antibiotic resistance is a global crisis that knows no borders, and global surveillance is becoming an essential vehicle to monitor and control its dissemination. Near-instantaneous tracking enables health authorities to see when new resistance trends emerge and respond in real time to outbreaks and efforts to curb the resistance. The Global Antimicrobial Resistance Surveillance System (GLASS) of the World Health Organization is an essential endeavor to stimulate countries to collect, standardize, and disseminate resistance data (WHO, 2020). GLASS supports the harmonization of international responses to new and reemerging health threats through data sharing and policy harmonization. But many countries do not have infrastructure or resources for strong national surveillance. They can be supported by higher-income countries in financing, training, and transferring technology to ensure universal implementation worldwide. Meanwhile, genomics sequencing technologies are transforming surveillance by enabling researchers to identify resistance genes and follow the evolution of pathogens in real time. The COVID-19 pandemic illustrated the potential for genomic surveillance to be a crucial tool in countering global health threats. If we could invest that same urgency and collaboration into antimicrobial resistance, we could reduce the speed and rate at which it can spread. Building well-functioning, global response systems will take more than just technical investments, however; it will also take political will, global collaboration, and transparency. It is only through international vigilance that the march of resistant pathogens may be slowed or halted.

Fifth, raising public awareness of the risks of antibiotic misuse is key to behavioral change at the community level. Many people continue to wrongly think that antibiotics can cure viral illnesses like the flu and COVID-19. This misunderstanding leads to irrational prescribing and self-medication, particularly in areas where antibiotics are available over the counter. Education atthe school level is necessary for children in hygienic practices, prevention of disease, and responsible use of medicine. Healthcare workers should be educated to explain clearly to patients the reasons why antibiotics may not be indicated in some cases. Patients should also be educated about following the full course of prescribed treatment and not "saving" or sharing remaining antibiotics. Mass media advertisements, public service announcements, and social media outlets can also be utilized to disseminate credible information. It is especially important to target programs for rural or underserved populations. Often, these communities face barriers to healthcare access and lower health literacy, making them more susceptible to misinformation. Mobile clinics, community health workers, and local workshops can offer culturally sensitive information and empower people to live healthfully. Public health campaigns, studies have found, can produce measurable declines in antibiotic usage. For instance, a nationwide campaign in France resulted in a 26.5% decrease in the antibiotic consumption over a period of five years (Sabuncu et al.). By enabling the population through knowledge, we convert education and outreach into valuable instruments in the worldwide fight to save antibiotic efficiency.

5. Conclusion

The worldwide increase of antibiotic resistance creates a major crisis that endangers both essential medical treatments and modern medical advancements. The crisis develops from antibiotic misuse throughout healthcare facilities and agricultural operations, and environmental sectors, while infectious diseases persist and pathogens develop resistance. The severe outcomes of increased mortality rates and economic losses require immediate attention. The fight against antibiotic resistance can be slowed through better stewardship practices and policy reforms and research investments, and public education campaigns to safeguard public health for upcoming generations. The time to take action is immediate because antibiotics are at risk of losing their effectiveness.

References

[1] Centers for Disease Control and Prevention. (2019). Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

[2] European Medicines Agency. (2022). Antimicrobial resistance. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/antimicrobial-resistance

[3] Karanika, S., Paudel, S., Grigoras, C., Kalbasi, A., Mylonakis, E. (2016). Systematic review and meta-analysis of clinical and economic outcomes from antimicrobial stewardship programs in hospitals. Antimicrobial Agents and Chemotherapy, 60(8), 4840–4852. https://doi.org/10.1128/AAC.00825-16

[4] O'Brien, K. L., Wolfson, L. J., Watt, J. P., et al. (2009). Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. The Lancet, 374(9693), 893–902. https://doi.org/10.1016/S0140-6736(09)61204-6

[5] Sabuncu, E., David, J., Bernède-Bauduin, C., Pépin, S., Leroy, M., Boëlle, P. Y., & Guillemot, D. (2009). Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. PLoS Medicine, 6(6), e1000084. https://doi.org/10.1371/journal.pmed.1000084

[6] Brockmann, D., & Helbing, D. (2013). The hidden geometry of complex, network-driven contagion phenomena. Science, 342(6164), 1337–1342. https://doi.org/10.1126/science.1245200

[7] Food and Drug Administration. (2021). 2020 summary report on antimicrobials sold or distributed for use in food-producing animals. https://www.fda.gov/media/154820/download

[8] Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., et al. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. The Lancet Infectious Diseases, 10(9), 597–602. https://doi.org/10.1016/S1473-3099(10)70143-2

[9] Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. P & T: A Peer-Reviewed Journal for Formulary Management, 40(4), 277–283.

[10] World Health Organization. (2020). Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

[11] Centers for Disease Control and Prevention. (2019). Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

[12] Klein, E. Y., Mojica, N., Jiang, W., et al. (2019). Trends in antibiotic resistance in U.S. hospitals. New England Journal of Medicine, 371(9), 822–832.

[13] Larsson, D. G. J., Andremont, A., Bengtsson-Palme, J., et al. (2018). Critical knowledge gaps and research needs related to the environmental dimensions of antibiotic resistance. Environment International, 117, 132–138.

[14] Rawson, T. M., Moore, L. S. P., Castro-Sanchez, E., et al. (2020). COVID-19 and the potential long-term impact on antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 75(7), 1681–1684.

[15] Cleveland Clinic (2023, October 19). Antibiotic Resistance. Retrieved June 13, 2025, from https://my.clevelandclinic.org/health/articles/21655-antibiotic-resistance.